A 2025 American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (AUA/CUA/SUFU) guideline update recommends that clinicians offer cranberry as an option for prophylaxis in women with recurrent urinary tract infections (UTIs), classified as a moderate recommendation with Grade B evidence. The guideline describes proanthocyanidins (PACs) as the proposed mediators of cranberry’s ability to prevent bacterial adhesion to the urothelium. A cited meta-analysis supports cranberry supplements standardized to at least 36 mg of PACs, reporting greater effectiveness in reducing UTI recurrence than products containing less than 36 mg; however, many commercial products lack documented validation of PAC dosage. Two recent randomized controlled trials involving 218 participants demonstrated reduced UTI rates with cranberry prophylaxis compared with placebo. Additionally, a 2024 systematic review and network meta-analysis of 20 trials involving more than 3,000 participants compared cranberry juice, cranberry tablets, and increased fluid intake for UTI prevention and management. As summarized in the guideline, cranberry juice consumption was associated with a 54% lower UTI rate, reduced antibiotic use by up to 50%, and significantly fewer UTI symptoms compared with no treatment. Although clinical studies have not routinely reported adverse effects, the guideline states that available evidence suggests minimal potential harms from cranberry use. [1]
A 2023 Cochrane systematic review of 50 randomized or quasi-randomized trials involving 8,857 participants evaluated cranberry products for preventing UTIs, with searches conducted through March 13, 2023. Compared with placebo, water, or no specific treatment, cranberry products reduced the risk of symptomatic, culture-verified UTIs (26 studies; 6,211 participants; risk ratio [RR] 0.70; 95% confidence interval [CI] 0.58 to 0.84; I²= 69%; moderate-certainty evidence). Subgroup analyses demonstrated reduced risk in women with recurrent UTIs (8 studies; 1,555 participants; RR 0.74; 95% CI 0.55 to 0.99; moderate-certainty evidence), children (5 studies; 504 participants; RR 0.46; 95% CI 0.32 to 0.68; moderate-certainty evidence), and individuals susceptible to UTIs following an intervention (6 studies; 1,434 participants; RR 0.47; 95% CI 0.37 to 0.61; low-certainty evidence). However, cranberry products may provide little or no benefit in institutionalized older adults (3 studies; 1,489 participants; RR 0.93; 95% CI 0.67 to 1.30), pregnant women (3 studies; 765 participants; RR 1.06; 95% CI 0.75 to 1.50), or adults with neuromuscular bladder dysfunction and incomplete bladder emptying (3 studies; 464 participants; RR 0.97; 95% CI 0.78 to 1.19). Compared with antibiotic prophylaxis, cranberry products may make little or no difference in symptomatic, culture-verified UTI risk (2 studies; 385 participants; RR 1.03; 95% CI 0.80 to 1.33). Gastrointestinal adverse events probably differed little or not at all between cranberry and placebo or no specific treatment (10 studies; 2,166 participants; RR 1.33; 95% CI 1.00 to 1.77; moderate-certainty evidence). Evidence was insufficient to determine whether efficacy differed between cranberry juice and tablets or between different proanthocyanidin doses. The authors concluded that cranberry products reduce symptomatic, culture-verified UTIs in women with recurrent UTIs, children, and individuals susceptible to UTIs following interventions; available evidence did not support their use in the other populations evaluated. [2]
A 2024 network meta-analysis of 20 controlled trials (18 randomized and 2 nonrandomized; 3,091 participants, 88.8% female) evaluated cranberry juice, cranberry tablets, and other liquids for UTI prevention. In the network meta-analysis of 18 studies reporting UTI rates, cranberry juice reduced the rate of UTIs by 27% compared with placebo liquid (rate ratio 0.73; 95% CI 0.59 to 0.91; p= 0.005; moderate-certainty evidence) and by 54% compared with no treatment (rate ratio 0.46; 95% CI 0.31 to 0.68; p<0.0001; very-low-certainty evidence). Excluding one study at high risk of bias reduced the estimated reduction versus no treatment from 54% to 49%. Evidence was insufficient to establish differences in UTI rates between cranberry tablets and placebo liquid, no treatment, or cranberry juice. A separate network meta-analysis of six studies found lower antibiotic use with cranberry juice versus placebo liquid (rate ratio 0.51; 95% CI 0.30 to 0.87; p= 0.014). The authors concluded that the evidence supports cranberry juice for UTI prevention; limitations included variation in definitions of recurrent UTIs, lack of participant and personnel blinding in nine studies, educational interventions accompanying cranberry supplementation in some studies, and insufficient male participants to permit comparisons by sex. [3]
A 2024 meta-analysis of 10 randomized controlled trials involving 2,438 participants evaluated the effectiveness of cranberry products for preventing UTIs, with particular emphasis on daily proanthocyanidin (PAC) intake. Included populations comprised women with recurrent UTIs, patients undergoing surgery, nursing home and long-term care residents, and older hospitalized patients; follow-up ranged from 10 days to 48 weeks. Cranberry products included juice and capsules, and comparators included placebo, low-dose PACs, or standard management. Overall, cranberry products reduced UTI risk by 15% compared with controls (relative risk 0.85; 95% CI 0.76 to 0.96; p= 0.008). In analyses stratified by PAC intake, consumption of ≥36 mg/day reduced UTI risk by 18% (RR 0.82; 95% CI 0.69 to 0.98; p= 0.03), whereas intake of <36 mg/day did not significantly reduce risk (p= 0.39). Subgroup analyses identified a significant reduction with cranberry use for 12 to 24 weeks (RR 0.75; 95% CI 0.61 to 0.91; p= 0.004), which remained significant after Bonferroni correction; reductions were not statistically significant with use for <12 weeks or 24 to 48 weeks. Although the female-only subgroup initially demonstrated a significant reduction (RR 0.84; 95% CI 0.71 to 0.98), this finding did not remain significant after correction for multiple comparisons. Limitations included the limited number and sample sizes of eligible trials, variable study quality, losses to follow-up, and differing UTI definitions based on symptoms, urine cultures, or both. The authors concluded that PAC dose and duration of cranberry use warrant consideration and that larger, high-quality randomized trials are needed to further evaluate these factors. [4]
A 2022 narrative review investigated the use of cranberry products to reduce the recurrence (secondary prevention) of urinary tract infections (UTIs) in older patients. Six systematic review articles of patients with or without recurrent UTIs were included for analysis. All patients were older than 65 years, and most were female from age-care or hospital settings. Interventions greatly varied, including juice, capsules, extracts, and powder formulations. While all studies found some level of support for regular cranberry administration to reduce UTI recurrence versus placebo, one systematic review reported non-significant trends. Their analysis of 15 studies noted that each study was non-significant in reducing symptomatic UTI, and the authors could not support their use as prevention in older patients with urinary catheters. Some systematic reviews note that cranberry capsules demonstrate favorable efficacy, specifically twice daily consumption of cranberry capsules (containing at least 36 mg proanthocyanidins [PCAs]). Adverse event rates were generally mild. The narrative review offers some understanding of cranberry product trends but lacks statistical analysis to validate potential benefits. [5]
A 2021 meta-analysis reviewed the effects of cranberry as adjuvant therapy on the recurrence rate of urinary tract infections in susceptible groups. Among 23 included randomized controlled trials (RCTs; N= 3,979), 15 trials administered cranberry juice, one used both cranberry juice and cranberry tablets, and twelve used cranberry capsules, with daily cranberry amounts ranging from 0.4 to 194.4 g. A subgroup analysis based on the formulation of cranberry-containing products found a relative risk reduction of 35% in patients who used cranberry juice versus cranberry capsules or tablets (risk ratio [RR] 0.65; confidence interval [CI] 0.54 to 0.77). Researchers found 13 studies that evaluated the use of cranberry juice to prevent UTIs (RR 0.65; CI 0.54 to 0.77; I2= 33%) and 10 studies that assessed the same outcome with cranberry capsules or tablets (RR 0.8; CI 0.7 to 0.91; I2= 52.7%). Large volumes of cranberry juice are required, and the sugar content may lead to severe gastrointestinal issues; however, the authors still suggest cranberry in juice form may be more favorable than cranberry in capsules or tablets for the desired result. Throughout the evaluated studies, there was no consistency among the levels of PACs, the active ingredient of cranberry products, believed to provide UTI prevention. The proposed daily recommended dose of PACs is 36 mg. These findings may have led to inconsistencies in the results. Of note, the compiled results did not show a significant decrease in recurrent UTIs in patients with neuropathic bladder, pregnant patients, or elderly patients. [6]
According to a 2017 meta-analysis, cranberry may be effective in preventing UTI recurrence in generally healthy women. This analysis included data from seven randomized controlled trials conducted in healthy women at risk of UTI (N= 1,498). Results showed that cranberry reduced the risk of UTI by 26% (pooled RR 0.74; 95% CI 0.55 to 0.98). Overall, the studies were relatively small, with only two having more than 300 participants. Although the authors state that cranberry may be useful in recurrent UTI prevention, they also mention that larger high-quality studies are needed to confirm these findings. Similarly, there is a lack of robust data regarding the optimum dosage and formulation of cranberry-derived active compounds (i.e., juice, tablet, capsule, or powder) in this setting. [7]
A 2016 study discussed the need for an alternative prophylactic approach to antibiotics in the case of UTIs. This article further detailed the anti-adhesion properties of cranberry due to the PAC component and tested the PAC levels in seven commercially available cranberry supplements (formulation not specified). Four of the seven products showed no anti-adhesion. The other three products' PAC levels ranged from 4 mg/g to 175 mg/g, with the highest PAC level showing the most anti-adhesion. This article also noted that clinical trials in the past have determined that at least 36 mg of PAC is required to result in significant reductions in recurrent UTIs. Similarly, the variability in quality of supplements available to consumers should be recognized. [8]